Sanaz N. Ghafouri

CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

Sarah Larson, Christopher M. Walthers, Brenda Ji et al. · Cancer Discovery · 2022 · 101 citations · Full text

Life Sciences, Immunology, Oncology +17

Axicabtagene Ciloleucel CAR T-cell therapy for relapsed/refractory secondary CNS non-Hodgkin lymphoma: comparable outcomes and toxicities, but shorter remissions may warrant alternative consolidative strategies?

Sanaz N. Ghafouri, John M. Timmerman, Sarah M. Larson et al. · Bone Marrow Transplantation · 2020 · 55 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Real-World Experience of Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed or Refractory Aggressive B-cell Lymphomas: A Single-Institution Experience

Sanaz N. Ghafouri, Kathleen E. Fenerty, Gary J. Schiller et al. · Clinical Lymphoma Myeloma & Leukemia · 2021 · 25 citations · Full text

Medicine, Hematology, Oncology +17

Treating Penile Cancer in the Immunotherapy and Targeted Therapy Era

Gavin Hui, Sanaz N. Ghafouri, John Shen et al. · Case Reports in Oncological Medicine · 2019 · 19 citations · Full text

Medicine, Immunology, Oncology +17

Immune reconstitution inflammatory syndrome, human herpesvirus 8 viremia, and HIV-associated multicentric Castleman disease

Marc Siegel, Sanaz N. Ghafouri, Ravi K. Ajmera et al. · International Journal of Infectious Diseases · 2016 · 14 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +13